Gilead Sciences, Inc. $GILD Shares Purchased by HUB Investment Partners LLC

Key Points

• HUB Investment Partners boosted its stake in Gilead by 18% to 58,449 shares (about $6.49M) in the third quarter, and institutional investors now own roughly 83.7% of the stock, with other firms like Aptus and Crossmark also materially increasing positions.
• Gilead beat quarterly estimates (EPS $1.86 vs. $1.83 expected; revenue $7.93B vs. $7.68B) and set FY2026 guidance of $8.45–$8.85 EPS, versus analyst forecasts around $7.95.
• The board raised the quarterly dividend to $0.82 ($3.28 annualized, ~2.3% yield), even as insiders sold about 309,280 shares (~$43.9M) last quarter; analysts maintain a consensus rating of "Moderate Buy" with a target near $156.72.

HUB Investment Partners LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 58,449 shares of the biopharmaceutical company's stock after purchasing an additional 8,913 shares during the quarter. HUB Investment Partners LLC's holdings in Gilead Sciences were worth $6,488,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Modern Wealth Management LLC lifted its position in Gilead Sciences by 1.2% during the 3rd quarter. Modern Wealth Management LLC now owns 8,175 shares of the biopharmaceutical company's stock worth $907,000 after acquiring an additional 97 shares in the last quarter. Foster Dykema Cabot & Partners LLC acquired a new position in shares of Gilead Sciences during the third quarter worth $57,000. Aptus Capital Advisors LLC lifted its position in shares of Gilead Sciences by 241.8% during the third quarter. Aptus Capital Advisors LLC now owns 77,080 shares of the biopharmaceutical company's stock worth $8,556,000 after purchasing an additional 54,526 shares in the last quarter. Consolidated Portfolio Review Corp purchased a new position in shares of Gilead Sciences in the third quarter valued at $294,000. Finally, Crossmark Global Holdings Inc. grew its holdings in Gilead Sciences by 3.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 528,203 shares of the biopharmaceutical company's stock valued at $58,630,000 after purchasing an additional 15,182 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $144.08 on Friday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The firm's 50-day simple moving average is $138.29 and its 200-day simple moving average is $125.75. The firm has a market cap of $178.86 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 1.90 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same period in the previous year, the company earned $1.90 earnings per share. Gilead Sciences's quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's payout ratio is 46.68%.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the sale, the chief financial officer owned 167,779 shares of the company's stock, valued at approximately $25,910,110.97. The trade was a 1.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 309,280 shares of company stock worth $43,935,470 in the last quarter. Insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on GILD. Daiwa Securities Group lifted their price target on shares of Gilead Sciences from $129.00 to $161.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Gilead Sciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, January 23rd. Truist Financial lifted their target price on Gilead Sciences from $145.00 to $152.00 and gave the stock a "buy" rating in a research report on Wednesday, February 11th. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $150.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 11th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Gilead Sciences from $135.00 to $155.00 and gave the company a "buy" rating in a report on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $156.72.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.